Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Evelien Bergrath Washington"'
Autor:
Kyle Fahrbach, Jialu Tarpey, Evelien Bergrath Washington, Rachel Hughes, Howard Thom, Maureen P. Neary, Amy Cha, Robert Gerber, Joseph C. Cappelleri
Publikováno v:
Dermatology and Therapy, Vol 10, Iss 6, Pp 1441-1444 (2020)
The authors would like to replace 2 small sections of the published manuscript that refer to a qualitative review of safety data for included studies (together with an associated safety table), to provide some further clarifications on these safety d
Externí odkaz:
https://doaj.org/article/bca3862da68f4ffd9fd2703922160fb0
Autor:
Kyle Fahrbach, Jialu Tarpey, Evelien Bergrath Washington, Rachel Hughes, Howard Thom, Maureen P. Neary, Amy Cha, Robert Gerber, Joseph C. Cappelleri
Publikováno v:
Dermatology and Therapy, Vol 10, Iss 4, Pp 681-694 (2020)
Abstract Introduction There is a need to compare efficacy and safety profiles of crisaborole ointment, 2%, versus other topical treatments across randomized clinical trials (RCTs). We performed this review/network meta-analysis to evaluate the compar
Externí odkaz:
https://doaj.org/article/eaf84075afdd4249822d8605c1516207
Autor:
Amy Cha, Maureen P Neary, Jialu Tarpey, Rachel Hughes, Kyle Fahrbach, Evelien Bergrath Washington, Howard Thom, Joseph C. Cappelleri, Robert A. Gerber
Publikováno v:
Dermatology and Therapy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c9bfc33bdb1eeaef5bbb9d0be487cbab
http://europepmc.org/articles/PMC8611131
http://europepmc.org/articles/PMC8611131
Autor:
Odette S. Reifsnider, Pratik Pimple, Sarah Brand, Evelien Bergrath Washington, Sharash Shetty, Nihar R. Desai
Publikováno v:
Diabetes, obesitymetabolism. 24(4)
To estimate the cost-effectiveness of sequential use of the sodium-glucose co-transporter-2 inhibitor empagliflozin and glucagon-like peptide-1 receptor agonist liraglutide after metformin in patients with type 2 diabetes (T2D) from the US payer pers
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d368ac4c02b80557b7f6ab164a747d04
https://pubmed.ncbi.nlm.nih.gov/34910356
https://pubmed.ncbi.nlm.nih.gov/34910356
Autor:
null Odette S. Reifsnider, null Pratik Pimple, null Sarah Brand, null Evelien Bergrath Washington, null Sharash Shetty, null Nihar R. Desai
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f8a2c5948c975b30090d8c366a397c5d
https://doi.org/10.1111/dom.14625/v2/response1
https://doi.org/10.1111/dom.14625/v2/response1
Autor:
Kyle Fahrbach, Amy Cha, Joseph C. Cappelleri, Rachel Hughes, Jialu Tarpey, Howard Thom, Robert A. Gerber, Maureen P Neary, Evelien Bergrath Washington
Publikováno v:
Fahrbach, K, Tarpey, J, Bergrath, E, Hughes, R, Thom, H H Z, Neary, M, Cha, A, Gerber, R & Cappelleri, J 2020, ' Crisaborole Ointment, 2%, for Treatment of Patients with Mild-to-Moderate Atopic Dermatitis : Systematic Literature Review and Network Meta-Analysis ', Dermatology and Therapy, vol. 10, pp. 681–694 . https://doi.org/10.1007/s13555-020-00389-5
Dermatology and Therapy
Dermatology and Therapy, Vol 10, Iss 4, Pp 681-694 (2020)
Dermatology and Therapy
Dermatology and Therapy, Vol 10, Iss 4, Pp 681-694 (2020)
Introduction There is a need to compare efficacy and safety profiles of crisaborole ointment, 2%, versus other topical treatments across randomized clinical trials (RCTs). We performed this review/network meta-analysis to evaluate the comparative eff
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8e57a84be1bf18412fae845d7b2fb1b3
https://research-information.bris.ac.uk/en/publications/c4a8c146-24f0-4006-aa54-6259453d9413
https://research-information.bris.ac.uk/en/publications/c4a8c146-24f0-4006-aa54-6259453d9413